This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: John David Blyth: Innovator in Pharmaceutical Composition
Introduction
John David Blyth is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative compositions. His work is recognized for its potential impact on medical treatments.
Latest Patents
John David Blyth holds a patent for a pharmaceutical composition identified as Composition 064. This composition comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide combined with mannitol and/or 5 microcrystalline cellulose. This patent showcases his expertise in developing effective pharmaceutical solutions.
Career Highlights
Throughout his career, Blyth has been associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca has allowed him to work on groundbreaking research and development projects that aim to improve patient outcomes.
Collaborations
John David Blyth has collaborated with notable colleagues, including Andrew John Day and Kieran James Lennon. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of pharmaceutical sciences.
Conclusion
John David Blyth is a distinguished inventor whose work in pharmaceutical compositions has the potential to make a significant impact in the medical field. His contributions, particularly through his patent, highlight his commitment to advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile